TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Permanent Discontinuation of LDV/SOF Due to an Adverse Event
Endpoint domain: Adverse events/effects
Primary endpoint: Area under the curve (AUC) of the analyte in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Index of the absorption rate Cpmax/AUCt
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle Strength Loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Safety and tolerability of belimumab
Endpoint domain: Adverse events/effects
Primary endpoint: Invasive Disease-free Survival (iDFS)
Endpoint domain: Mortality/survival
Primary endpoint: CPAP use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: General Organization Index (GOI)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Patient response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative Surgical Site Infection
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperative Procalcitonin Plasma Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Postoperative C-Reactive Protein Plasma Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Incidence of Hypothermia
Endpoint domain: Adverse events/effects
Primary endpoint: Anti-tumor immune response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Flow Mediated Dilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Performance in individual tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with Treatment Emergent Adverse Events (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in DAS28-4/ESR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in DAS28-4/CRP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Physician Global Assessment (VAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 12-week Sustained Virologic Response (SVR12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in body composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Frequency of subjects with serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of subjects reporting solicited local reactions after first study injection
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of subjects reporting solicited systemic reactions after first study injection
Endpoint domain: Adverse events/effects
Primary endpoint: VAS score < 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage stent strut coverage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with tumor recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Participants With Laboratory Abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Change From Baseline in Percentage of Parabasal Cells in Maturation Index of Vaginal Smear
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Mean Change From Baseline in Percentage of Superficial Cells in Maturation Index of Vaginal Smear
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Mean Change From Baseline in Vaginal pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: brain-derived neurotrophic factor levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Current pain assessed by numeric rating scale (NRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Autonomic Nervous System Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of Patellar Crepitus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mouth opening in centimeters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Kidney Preservation After Preoperative Chemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Percentage of Patients Who Experienced Partial Nephrectomy After Preoperative Chemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Patients With Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Best Overall Response (BOR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of long-term treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Asthma Control Test
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Overall Adverse Event Summary
Endpoint domain: Adverse events/effects
Primary endpoint: Diabetic Ketoacidosis (DKA)
Endpoint domain: Adverse events/effects
Primary endpoint: Severity of Airway Interruption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Quality of Operative Field
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Cmax of KD025 and KD025m2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of KD025m1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of KD025, KD025m1, and KD025m2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-inf) and AUC(0-24) of KD025 and KD025m2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC(0-24) of KD025m1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression-free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Total Amount of Alcohol Consumed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor-antigen-specific Immunity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Area under plasma concentration time curve from zero to infinity (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Half life associated with terminal slope (λz)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participant Incidence of Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Reintegration to Normal Living Index (RNLI)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Geometric Mean Area Under Curve (AUC) of Cyclophosphamide (CP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric Mean Area Under Curve (AUC) of 2-dechloro-cyclophosphamide (2-deCI-CP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric Mean Area Under Curve (AUC) of 4-hydroxy-cyclophosphamide (4-OH-CP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric Mean Area Under Curve (AUC) of Vincristine (VC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability in terms of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change from Baseline Dosage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Intervention Dosage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Post-Intervention Dosage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postprandial metabolic response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Postprandial inflammatory response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Postprandial endothelial response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Irritable Bowel Syndrome - Impact Scale (IBS-IS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Motor function as measured by UPDRS part 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Medication Adherence at 3-month Follow-up Assessment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percent Medication Adherence at 12-month Follow-up Assessment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Blood Lactate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: iGFR change over a one year time period
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Bone mineral density DXA score changes for hip and lumbar vertebrae
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: incidence of postoperative agitation
Endpoint domain: Adverse events/effects
Primary endpoint: severity of postoperative agitation
Endpoint domain: Adverse events/effects
Primary endpoint: Change in phosphorylation levels of other biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in phosphorylation levels of v-akt murine thymoma viral oncogene homolog 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MTD of combination of cixutumumab and temsirolimus
Endpoint domain: Adverse events/effects
Primary endpoint: Tumor metabolism as assessed by PET scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Durability of antiretroviral regimen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fever
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: detection rate of 18F- Fluciclovine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With a 50% or More Decrease in BASDAI Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With a DAS28 Decrease ≥1.2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Active Axial Symptoms in Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline pelvic floor muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of Emergency Department Visits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Daytime asthma symptom frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Asthma-related quality of life score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: disease specific patterns of pathology on cranial MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: disease specific patterns of pathology in optical coherence tomography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serological biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of asymptomatic Deep Venous Thrombosis (DVT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Ocular Discomfort Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amyloid beta peptide 40 (Ab40) levels in Cerebrospinal Fluid (CSF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: reduction of Mayo endoscopic inflammation score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Menopause Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage brain volume change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: dose limiting toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in adipose tissue characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Coracoacromial ligament thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acromial angle (delta angle)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acromioglenoid angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Axial supraspinatus glenoid angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coronal supraspinatus glenoid angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acromiohumeral distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ocular Itching
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: quitting smoking self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants With Acute Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Late Serious Adverse Events Greater Than 7 Days Post Procedure
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Ischemic Stroke, Systemic Embolism and Cardiovascular Death
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Major Bleeding Events
Endpoint domain: Adverse events/effects
Primary endpoint: Reliability of the headgear
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Durability of the headgear
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional graft evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Pain Freedom at 2 Hours After Initial Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Absence of the Most Bothersome Migraine-Associated Symptom Identified at Baseline at 2-Hours After Initial Dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Level of presence of viral or bacterial infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Level of expression of SHH and VEGF in varicose vein wall
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative Patency at 6 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom From Bleeding at 6 Months
Endpoint domain: Adverse events/effects
Primary endpoint: Severity of hepatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Lower Gastrointestinal Acute Graft-Versus-Host-Disease Treatment Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Time to Seizure Onset
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Test of Theory of mind
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Ambiguous Intentions Hostility Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning
Primary endpoint: Attributional Style Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Diagnostic Analysis of Nonverbal Accuracy, Taiwanese version
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Heart Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in heart rhythm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in heart valve function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: New somatic mutation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Thickness of the Affected Plantar Fascia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in patient reported quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Proportion of patients with hematological abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Pharmacokinetics of TXL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrent Instability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and specificity of diagnosis and staging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Daily Patient-reported Communication Difficulty Rating
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Major complication
Endpoint domain: Adverse events/effects
Primary endpoint: Change in alcohol use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of participants who received the first dose of COVID-19 vaccine
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Functional Activity and Strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle Mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time in ventilator-patient synchrony
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of Participants Who Died
Endpoint domain: Mortality/survival
Primary endpoint: Adverse Events (AEs) Leading to Discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Weeks Until Transferrin Saturation Stabilizes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weeks Until Ferritin Stabilizes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Transfusions per patient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Efficacy assessed by Unified Parkinson's Disease Rating Scale-Motor Examination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Efficacy assessed by modified AIMS dyskinesia scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Discontinuation of immunosuppression drugs
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of patients free from disease progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Patient reported ease of dilation
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: surgical intervention required
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Self reported pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Death or respiratory failure until Day 28
Endpoint domain: Mortality/survival
Primary endpoint: maximum cervical spine motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ability of dressing to autolytically debride wound
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in Non-Medical Use of Prescription Stimulant Medication Frequency
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Medical Misuse of Prescription Stimulant Medication
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Substance Use/Misuse Brief Screen/Assessment Tool (TAPS Tool)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of men with same overall diagnosis from 18F-FMAU PET/CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Proportion of men with all cancer lesions identified by 18F-FMAU PET/CT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of men completing both imaging procedures
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change From Baseline in Asthma Control Questionnaire (ACQ) Composite Scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: System Failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: spectrum of mutations in VPS13B
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline HbA1c
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence and nature of acute and late toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Post-challenge GLP-1 responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Area under the serum concentration-time curve (AUC(INF))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed serum concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Korean modified Barthel Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning